This is the first webinar in the BioTech series. Although BioTech is still quite young, it recently received its first Impact Factor. As EiC, I would like to give credit to the EBMs, the Reviewers, and the Editorial Office for their excellent work that allows us to give a first response, on average, 18 days after submission. It is a pleasure to thank them publicly.

The journal explores various areas of interest and publishes articles on the following topics:

∙ Medical biotechnology, including biopharmaceuticals, gene therapy, and applied immunology;
∙ Molecular diagnostics and therapeutics;
∙ Agricultural and food biotechnology, including genetically modified plants, plant breeding,, and crop improvement;
∙ Marine biotechnology;
∙ Environmental biotechnology, including bioremediation, biomining, phytoremediation, and monitoring;
∙ Microbiology biotechnology, including prokaryotic and eukaryotic cells, and applied microbial and cell physiology;
∙ Large-scale biology, including genomics, functional genomics, proteomics, structural genomics, and metabolomics;
∙ Computational biology, including bioinformatics, algorithms, and molecular modeling;
∙ Forensic biotechnology;
∙ Biosecurity;
∙ Ethics in biotechnology;
∙ Biotechnology regulation.

Today, we have two speakers from the medical field: doctors who conduct research and perform clinical procedures on seriously disabling genetic diseases. Dr. Alessandra Ferlini, a professor at the University Hospital of Ferrara, will discuss Duchenne muscular dystrophy. Dr. Marika Pane, a professor at the Catholic University of the Sacred Heart, will discuss spinal muscular atrophy. They will explain how research and clinical applications of gene therapy are progressively changing the life prospects of patients affected by these harmful diseases.

Date: 26 September 2024
Time: 3:00 p.m. CEST | 9:00 a.m. EDT | 9:00 p.m. CST Asia
Webinar ID: 874 8852 5352
Webinar Secretariat: journal.webinar@mdpi.com